Brokerages Set Bruker Co. (NASDAQ:BRKR) PT at $80.80

Shares of Bruker Co. (NASDAQ:BRKR) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $81.40.

Several research firms have recently commented on BRKR. TD Cowen lowered their price target on shares of Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a research report on Wednesday, August 7th. Stifel Nicolaus dropped their price target on shares of Bruker from $81.00 to $77.00 and set a “hold” rating on the stock in a research note on Monday, May 20th. The Goldman Sachs Group cut their price target on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Citigroup decreased their price objective on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. Finally, Wells Fargo & Company assumed coverage on Bruker in a research note on Tuesday. They set an “overweight” rating and a $78.00 target price on the stock.

Bruker Trading Up 4.9 %

NASDAQ BRKR opened at $67.59 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81. Bruker has a one year low of $53.79 and a one year high of $94.86. The company has a 50-day simple moving average of $63.85 and a 200-day simple moving average of $74.78. The firm has a market capitalization of $9.82 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 2.39 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.52. The business had revenue of $800.70 million for the quarter, compared to analysts’ expectations of $799.44 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.50 EPS. On average, equities analysts forecast that Bruker will post 2.66 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 16th. Investors of record on Monday, September 2nd will be paid a dividend of $0.05 per share. The ex-dividend date is Friday, August 30th. This represents a $0.20 annualized dividend and a yield of 0.30%. Bruker’s dividend payout ratio is currently 7.27%.

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the business. Maven Securities LTD increased its holdings in shares of Bruker by 400.0% in the second quarter. Maven Securities LTD now owns 20,000 shares of the medical research company’s stock valued at $1,276,000 after buying an additional 16,000 shares in the last quarter. Aristides Capital LLC acquired a new position in shares of Bruker in the 2nd quarter worth $222,000. Cetera Investment Advisers raised its position in shares of Bruker by 2.4% during the second quarter. Cetera Investment Advisers now owns 33,936 shares of the medical research company’s stock worth $2,165,000 after purchasing an additional 805 shares during the period. Susquehanna Fundamental Investments LLC lifted its holdings in shares of Bruker by 1,007.5% during the second quarter. Susquehanna Fundamental Investments LLC now owns 89,704 shares of the medical research company’s stock valued at $5,724,000 after purchasing an additional 81,604 shares during the last quarter. Finally, Scientech Research LLC boosted its position in shares of Bruker by 477.3% in the 2nd quarter. Scientech Research LLC now owns 12,879 shares of the medical research company’s stock valued at $822,000 after purchasing an additional 10,648 shares during the period. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.